Rottenberg Y, Grinshpun A, Ben-Dov IZ, et al. - Patients with solid tumors, primarily those treated with chemotherapy, exhibit lower immunogenic response to the BNT162b2 vaccine. In this study, the short-term (< 30 days) humoral response to a third (booster) shot has been evaluated in this population.

• Researchers assessed a total of 37 patients with cancer receiving active systemic therapy who underwent serologic testing after receiving a vaccine booster from August 15 to September 5, 2021.

• Among these patients, there appeared a generally positive and immediate antibody response to booster administration of the BNT162b2 vaccine.

• In line with other recent findings, this study suggests a swift, substantial response in comparable booster-dosed populations (eg, solid organ transplant recipients).